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67.6% were male. Based upon the questionnaire, 36.1%
of patients reported nonadherence. Lower adherence rate
(49.1%) was obtained when comparing medications 
prescribed at discharge to medications documented at
follow-up. Based on the questionnaire, the more medica-
tion prescribed, the greater the adherence (p = 0.02).
Trend tests of adherence over increasing number of 
medications were positive in all medication classes 
(beta-blockers, ACE inhibitors, anticoagulants, and lipid
lowering drugs). Multivariate models show the similar
trend when adjusted for age and gender. Adherence 
also increased with more documented comorbidities (p =
0.01). When comparing medications prescribed to med-
ications at follow-up there were no signiﬁcant predictors
of adherence.
CONCLUSIONS: Nonadherence is frequent in patients
after an MI (36%). Utilizing a medication adherence
questionnaire to assess adherence is better than merely
comparing medication lists at two different points in time.
Better adherence to all four evidence-based therapies after
an MI is seen in patients prescribed more medications 
and with more disease states. Higher adherence may be
related to a recent major health event, more recent edu-
cation on treatment beneﬁts, and/or to a focus on reha-
bilitation. This study demonstrates the need for a larger,
broader study that includes health beliefs, psychosocial
assessment, and other patient factors that may inﬂuence
compliance.
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Arthritis—rheumatoid and osteoarthritis—is one of the
most prevalent chronic conditions affecting nearly 50%
of persons over the age of 65.
OBJECTIVES: The objective of this study was to
compare cardiorenal events and costs between two COX-
2 inhibitors—celecoxib and rofecoxib.
METHODS: This was a retrospective analysis of medical
and pharmacy claims. All patients newly started on a
COX-2 inhibitor during 7/1/99 to 6/30/00 were identiﬁed
and followed for 6 months before and after the initial
COX-2 prescription. Incident cardiorenal events were
attributable to a COX-2 if there was an ICD-9 diagnosis
code within 45 days after the last days supply of the 
prescription.
RESULTS: A total of 20,514 patients were newly pre-
scribed celecoxib (n = 12,487) or rofecoxib (n = 8,027).
Mean age was 65 (+/-15) and 68% were female. Primary
indication for COX-2 was pain (55%), followed by
osteoarthritis (23%), other arthritis (17%), and rheuma-
toid arthritis (6%). There were no signiﬁcant differences
in baseline cardiorenal history and medication use
(antiarthritic, antihypertensive, and GI-related) between
the two cohorts. Among the baseline hypertensive
patients, those on rofecoxib were 34% more likely to
experience an incident cardiorenal event than patients on
celecoxib, adjusting for age, gender, comorbidity, indica-
tion and dosage (OR = 1.34; p = 0.007). Results were
similar for the baseline non-hypertensive patients, with
those on rofecoxib reporting a higher risk of new car-
diorenal events (OR = 1.18; p = 0.0009). Although not
statistically signiﬁcant, patients on rofecoxib incurred
slightly higher total health care costs than those on cele-
coxib ($8,188 vs. $7,540; p = 0.0867).
CONCLUSION: The risk of cardiorenal events was 
signiﬁcantly higher in rofecoxib-treated patients than
celecoxib-treated patients. There were no statistically sig-
niﬁcant differences in total costs between the two COX-
2 inhibitors, although celecoxib-treated patients incurred
slightly lower total health care costs.
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Osteoporosis affects 4–6 million women in the USA.
OBJECTIVES: The objective of this study was two-fold:
1) to evaluate treatment patterns of care associated 
with an incident fracture in postmenopausal women in a
managed care organization and 2) to estimate the inci-
dence of subsequent fractures by age.
METHODS: This was a retrospective analysis of medical
and pharmacy claims. Women aged 55 or older, with a
primary or secondary diagnosis of a new bone fracture
during calendar year 1999, and continuously enrolled in
the health plan were included in the sample. All claims
12-months before and 15-months after index fracture
date were evaluated for medication use and subsequent
fractures.
RESULTS: A total of 19,720 women had incident bone
fractures. Mean age was 78 years (+/-9.4). Of these
19,720 women, 90% had nonvertebral fractures, mainly
hip and wrist, and 10% had vertebral fractures. Overall
use of osteoporosis therapy, anytime before and after
index fracture, was 24% and 29%, respectively. Of the
women receiving therapy after fracture, 65% were 
prescribed estrogen, 28% bisphosphonates, 17% nasal
calcitonin, 14% combination therapy, primarily a bis-
phosphonate plus estrogen, and 5% raloxifene. Only
25% of treated women remained on therapy for at least
